Gerresheimer stock holds its ground as investors wait for fresh report signals

Gerresheimer (ISIN DE000A0LD6E6) remains a closely watched packaging and drug-delivery supplier, and its stock is being judged against the latest visible financial backdrop rather than a single trading headline. The company reported revenue of EUR 2.04 billion in fiscal 2025 and adjusted EBITDA of EUR 430.8 million, while adjusted earnings per share came in at EUR 2.38 for the year.

Revenue of EUR 2.04 billion

The fiscal 2025 revenue figure of EUR 2.04 billion gives the market a fresh benchmark for scale, while adjusted EBITDA of EUR 430.8 million shows how much operating profit the group extracted from that sales base. Adjusted EBITDA margin therefore worked out at 21.1% in fiscal 2025, which is the ratio investors tend to compare with prior years and guidance.

Net financial debt stood at EUR 1.88 billion at the end of fiscal 2025, a second number that matters because leverage shapes the room for acquisitions, capex, and shareholder returns. The combination of EUR 2.04 billion in revenue, EUR 430.8 million in adjusted EBITDA, and EUR 1.88 billion in net financial debt is the key arithmetic behind the stock story.

Profitability still sets the tone

Adjusted EPS of EUR 2.38 in fiscal 2025 shows that earnings remained positive even as debt stayed elevated. That creates a straightforward comparison for future quarters: if revenue advances faster than costs, EBITDA and EPS should give the market clearer evidence of operating leverage.

The latest annual numbers also help frame valuation discussions because the business is not only a growth story, but also a margin story. For a company serving pharmaceutical and healthcare customers, the question is whether future revenue can keep supporting an adjusted EBITDA margin above 20%.

Drug delivery is the product focus

Gerresheimer’s product mix is anchored in drug containment and drug delivery systems, which are the most relevant items to watch when the market prices in growth and margin stability. The group’s pharmaceutical packaging exposure means contract wins, volume trends, and mix shift all matter more than broad industrial sentiment.

That is why the annual numbers carry more weight than a simple business description. Revenue of EUR 2.04 billion, adjusted EBITDA of EUR 430.8 million, and adjusted EPS of EUR 2.38 together define the operating quality investors will test against the next report.

Annual numbers matter most

Gerresheimer stock is best read through the lens of its annual reporting base and balance-sheet structure. With EUR 1.88 billion in net financial debt and a 21.1% adjusted EBITDA margin in fiscal 2025, the company still has to prove that growth can translate into durable cash generation.

The stock narrative therefore rests on execution rather than slogans. If future periods show higher revenue with stable or better margins, the current fiscal 2025 benchmark will become a useful comparison point for the next reassessment.